Bambusa Therapeutics has dosed the first subject in a Phase 1 trial of BBT001, a novel half-life extended bispecific antibody designed to treat atopic dermatitis through multiple mechanisms of action.
Bambusa Therapeutics has raised $90 million in Series A financing led by RA Capital Management to advance its pipeline of bispecific antibodies for immunological and inflammatory disorders.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.